OPM 3023

Drug Profile

OPM 3023

Alternative Names: OPM-3023

Latest Information Update: 09 Jun 2015

Price : $50

At a glance

  • Originator Bionetworks
  • Developer onepharm; The Forsyth Institute
  • Class Anti-inflammatories
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Periodontitis; Rheumatoid arthritis

Most Recent Events

  • 03 Mar 2011 Investigation of locally administered formulation in Periodontitis in Austria (unspecified route, controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top